Medicare to cover costs of new test for AR-V7

We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …

New test now available for identification of AR-V7 mutations in mCRPC

According to a media release issued yesterday, Genomic Health has now made available a commercial test for risk of the AR-V7 mutation in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Testing for AR-V7 “validated” in men with CRPC

According to an article yesterday on Cancer Therapy Advisor, testing for circulating tumor cell (CTC)-based androgen receptor splice variant-7 (AR-V7) has now been validated as a prognostic test for men with castration-resistant prostate cancer (CRPC) receiving hormone therapy. … READ MORE …

An update on development of galeterone in the treatment of mCRPC

In a statement from Tokai Pharmaceuticals, the company has provided additional information about the clinical development of the investigational drug galeterone in treatment of metastatic, castration resistant prostate cancer (mCRPC). … READ MORE …

Tokai initiates trial of galeterone in men with AR-V7-positive mCRPC

According to information released earlier today by Tokai Pharmaceuticals, the company has started to enroll patients with AR-V7-positive, metastatic, castration-resistant prostate cancer (mCRPC) into a randomized Phase III clinical trial of treatment with galeterone. … READ MORE …

Can galeterone show effectiveness in men with AR-V7 mCRPC?

According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …

AR-V7 and resistance to treatment with enzalutamide, abiraterone

We have previously commented on early reports that prostate cancer patients carrying the androgen receptor subtype known as AR-V7 (the “isoform” encoded by splice variant 7) exhibit a high level of resistance to treatment with both enzalutamide (Xtandi) and abiraterone acetate (Zytiga). … READ MORE …